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Purpose or Objective: To review our outcomes for patients 
in the active inflammatory phase of moderate-to-severe 
Graves’ ophthalmopathy (GO) treated with combined 
systemic pulsed corticosteroids plus irradiation and 
demonstrate the role of magnetic resonance imaging (MRI) as 
a prognostic factor. 
 
Material and Methods: From our database of 35 patients 
treated with radiotherapy for the active inflammatory phase 
of GO in our hospital from January 2005 to December 2013, 5 
patients were excluded from the analysis because they had a 
short follow-up, were not treated with pulsed corticosteroids 
because of liver failure, or had no eye muscle impairment at 
diagnosis. In the remaining 30 patients in the active 
inflammatory phase of moderate-to-severe GO treated with 
combined pulsed corticosteroids plus irradiation, we assessed 
eye muscle impairment using the SPECS system before and 6 
months after the start of treatment. A total dose of 20 Gy in 
10 fractions was delivered to the bilateral retrobulbar 
volume. Intravenous 1 g of corticosteroids daily for 3 
successive days was repeated weekly up to 3 weeks. The 
thickness ratio (TR) of the enlarged eye muscle to the optic 
nerve and the signal intensity ratio (SIR) of the eye muscle to 
the cerebral white matter were evaluated as the mean of 
three cross sections of coronal short-time inversion recovery 
(STIR) sequence MRI to investigate whether these factors 
could predict the reversibility of eye muscle impairment. 
 
Results: This study included 10 men and 20 women with 
median age of 55.5 (range, 37–71) years. The thyroid function 
at the time of irradiation was euthyroid in 26 patients, 
hyperthyroid in 2, and hypothyroid in 2. Median duration of 
eye symptoms from onset to the initiation of radiotherapy 
was 4 months (range, 1.4–22.1 months). Six months after 
radiotherapy, there was a significant improvement in eye 
muscle impairment (p < 0.001); complete regression was 
observed in 10 patients (33%), partial regression in 5 (17%), 
no change in 14 (47%), and progressive disease in 1 (3%). The 
median TR was 4.1 (range, 0.4–16.4), and the median SIR was 
2.45 (range, 1.7–4.1). There was a trend toward greater, but 
not significant, improvement in patients with a low TR (<4.2) 
or high SIR (>2.5) before treatment. 
 
Conclusion: Orbital irradiation combined with pulsed 
corticosteroids was an effective treatment for the active 
inflammatory phase of moderate-to-severe GO, especially in 
patients with a low TR or high SIR on MRI before treatment. A 
low TR or high SIR may predict the treatment outcome. 
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Purpose or Objective: The radiotherapy treatment can 
produce a possible new second primary cancer, but 
metachronous malignancies can also appear without any 
relationship with radiotherapy treatment. We have studied 
the risk of developing a potential radiotherapy induced 
second cancer.  
 
Material and Methods: We analyse the new second cancers 
after a radiotherapy treatment for a primary cancer in a 
population-based study in a province of Spain from 2000 to 
2011.  
 
Results: The number of patients (pts) with cancer treated 
with radiotherapy during this period was 14131, 2989 were 
breast cancer, 2197 were prostate cancer and 1220 pts were 
rectal cancer. Three hundred and thirteen (2.2%) patients 
developed a second cancer after a primary cancer treated 
with radiotherapy. In relation to the primary cancer, the 
most frequent were prostate cancer (70 pts, 22.4%), the 
second breast cancer (43 pts, 13.7%), the third colorectal 
cancer (40 pts, 12.8%), the fourth skin cancer (36 pts, 11.5%) 
and the fifth larynx (24 pts). The others were bladder (20 
pts), oropharynx (7), endometrial cancer (6), etc. The most 
frequent of second cancer location was lung cancer (63 
cases, 20.1%), the second colorectal cancer (43 cases, 
13.7%), the third larynx and oral cavity and pharynx (40 
cases, 12.8%), breast (34, 10.9%), prostate (28, 8.9%), 
bladder (19.6%). The location more frequent after a prostate 
cancer irradiation is lung (20 pts) and colorectal (17 pts, 9 
rectal and 8 colon) and bladder (8). The location more 
frequent in after a breast cancer irradiation is another breast 
cancer (21 pts). Colorectal 40 pts: 9 second colorectal, 8 lung 
cancer. Non-melanoma skin cancer 36 pts: 8 second non-
melanoma skin cancer, 6 rectal cancer and 4 lung cancer. 
Larynx 24 pts: 7 lung cancer, 4 prostate cancers.  
 
Conclusion: The percentage of pts treated with radiotherapy 
who developed a second cancer after 11 years is 2.2% in our 
series. It’s difficult to know the real probability for 
developing a second cancer associated with radiotherapy. 
The higher percentage of primary tumour with second cancer 
was rectal cancer (40/1220, 3.27%), the second was prostate 
cancer (70/2197, 3.18%), the third was breast cancer 
43/2989, 1.43%). We’ll present the results about the location 
of second cancer, the time between the primary and the 
second cancer, and some characteristics about the 
radiotherapy treatment (total dose and other dosimetric 
characteristics).  
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Purpose or Objective: For many years Edinburgh Cancer 
Centre's radiotherapy skin care policy recommended aqueous 
cream and, if required, 1% hydrocortisone. However, it was 
increasingly appreciated that better alternatives existed so in 
2015, a review of the literature was performed, and a new 
skincare policy developed based on:  
1) Low Risk (treatment only if symptoms),  
2) Medium Risk (Diprobase moisturising cream),  
3) High Risk of developing radiation dermatitis (Diprobase & 
betamethasone valerate 0.1% applied once daily from 1st 
fraction till 14 days after treatment). The High Risk group 
included patients with breast, head and neck, anal, or pelvic 
cancers when body mass index >35 kg/m2.  
As concerns were raised about the increased cost and 
potential extent of the clinical benefit, a prospective audit 
was conducted. 
 
Material and Methods: For one month prior to the change of 
policy (cohort 1, C1), all patients in High Risk group 
completed a questionnaire at the end of their course of 
radiotherapy, scoring (categorical 0-10) their skin reaction 
for redness, itch, discomfort and pain, and asking what 
creams and analgesia they were using, and if the reaction 
disturbed their sleep. The audit was repeated for cohort 2 
(C2) four months after the policy changed and the two groups 
compared using Chi-squared and ANOVA. 
 
